These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

571 related items for PubMed ID: 18723564

  • 21. [Tumour necrosis factor alpha antagonists in established rheumatoid arthritis: effectiveness comparative study].
    Arenere Mendoza M, Manero Ruiz FJ, Carrera Lasfuentes P, Navarro Aznárez H, Pecondón Español A, Rabanaque Hernández MJ.
    Med Clin (Barc); 2010 May 22; 134(15):665-70. PubMed ID: 20363004
    [Abstract] [Full Text] [Related]

  • 22. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA, Klingman D, Hazard E, Ray S.
    Clin Ther; 2009 Apr 22; 31(4):825-35. PubMed ID: 19446156
    [Abstract] [Full Text] [Related]

  • 23. Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors.
    Iannone F, Gremese E, Atzeni F, Biasi D, Botsios C, Cipriani P, Ferri C, Foschi V, Galeazzi M, Gerli R, Giardina A, Marchesoni A, Salaffi F, Ziglioli T, Lapadula G, Gruppo Italiano di Studio sulle Early Arthritides (GISEA).
    J Rheumatol; 2012 Jun 22; 39(6):1179-84. PubMed ID: 22467933
    [Abstract] [Full Text] [Related]

  • 24. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data.
    Kievit W, Adang EM, Fransen J, Kuper HH, van de Laar MA, Jansen TL, De Gendt CM, De Rooij DJ, Brus HL, Van Oijen PC, Van Riel PC.
    Ann Rheum Dis; 2008 Sep 22; 67(9):1229-34. PubMed ID: 18174220
    [Abstract] [Full Text] [Related]

  • 25. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
    Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ, British Society for Rheumatology Biologics Register.
    Arthritis Rheum; 2007 Jan 22; 56(1):13-20. PubMed ID: 17195186
    [Abstract] [Full Text] [Related]

  • 26. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
    Gonnet-Gracia C, Barnetche T, Richez C, Blanco P, Dehais J, Schaeverbeke T.
    Clin Exp Rheumatol; 2008 Jan 22; 26(3):401-7. PubMed ID: 18578960
    [Abstract] [Full Text] [Related]

  • 27. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A.
    Int J Rheum Dis; 2012 Jun 22; 15(3):330-5. PubMed ID: 22709496
    [Abstract] [Full Text] [Related]

  • 28. Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows an excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors.
    Kita J, Tamai M, Arima K, Nakashima Y, Suzuki T, Kawashiri SY, Okada A, Koga T, Yamasaki S, Nakamura H, Origuchi T, Aramaki T, Nakashima M, Fujikawa K, Tsukada T, Ida H, Aoyagi K, Uetani M, Eguchi K, Kawakami A.
    Mod Rheumatol; 2012 Apr 22; 22(2):195-201. PubMed ID: 21898075
    [Abstract] [Full Text] [Related]

  • 29. Blockade of tumour necrosis factor {alpha} significantly alters the serum level of IgG- and IgA-rheumatoid factor in patients with rheumatoid arthritis.
    Yazdani-Biuki B, Stadlmaier E, Mulabecirovic A, Brezinschek R, Tilz G, Demel U, Mueller T, Brickmann K, Graninger WB, Brezinschek HP.
    Ann Rheum Dis; 2005 Aug 22; 64(8):1224-6. PubMed ID: 16014683
    [Abstract] [Full Text] [Related]

  • 30. Association of Baseline Peptidylarginine Deiminase 4 Autoantibodies With Favorable Response to Treatment Escalation in Rheumatoid Arthritis.
    Darrah E, Yu F, Cappelli LC, Rosen A, O'Dell JR, Mikuls TR.
    Arthritis Rheumatol; 2019 May 22; 71(5):696-702. PubMed ID: 30507066
    [Abstract] [Full Text] [Related]

  • 31. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
    Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register.
    Arthritis Rheum; 2006 Aug 22; 54(8):2368-76. PubMed ID: 16868999
    [Abstract] [Full Text] [Related]

  • 32. [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].
    González-Gay MA, Agudo M.
    Med Clin (Barc); 2010 May 22; 134(15):684-5. PubMed ID: 20176386
    [No Abstract] [Full Text] [Related]

  • 33. The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis.
    Arends S, Lebbink HR, Spoorenberg A, Bungener LB, Roozendaal C, van der Veer E, Houtman PM, Griep EN, Limburg PC, Kallenberg CG, Wolbink GJ, Brouwer E.
    Clin Exp Rheumatol; 2010 May 22; 28(5):661-8. PubMed ID: 20822711
    [Abstract] [Full Text] [Related]

  • 34. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes.
    Landewé R, van der Heijde D, Klareskog L, van Vollenhoven R, Fatenejad S.
    Arthritis Rheum; 2006 Oct 22; 54(10):3119-25. PubMed ID: 17009230
    [Abstract] [Full Text] [Related]

  • 35. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis.
    Maxwell JR, Potter C, Hyrich KL, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate, Barton A, Worthington J, Isaacs JD, Morgan AW, Wilson AG.
    Hum Mol Genet; 2008 Nov 15; 17(22):3532-8. PubMed ID: 18713756
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data.
    Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M.
    Curr Med Res Opin; 2007 Aug 15; 23(8):1749-59. PubMed ID: 17588306
    [Abstract] [Full Text] [Related]

  • 38. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis.
    Fernández-Nebro A, Irigoyen MV, Ureña I, Belmonte-López MA, Coret V, Jiménez-Núñez FG, Díaz-Cordovés G, López-Lasanta MA, Ponce A, Rodríguez-Pérez M, Calero E, González-Santos P.
    J Rheumatol; 2007 Dec 15; 34(12):2334-42. PubMed ID: 17985409
    [Abstract] [Full Text] [Related]

  • 39. Two novel sandwich ELISAs identify PAD4 levels and PAD4 autoantibodies in patients with rheumatoid arthritis.
    Ishigami A, Uchida Y, Miyazaki T, Handa S, Choi EK, Kim YS, Kasahara Y, Maruyama N.
    Mod Rheumatol; 2013 Jul 15; 23(4):794-803. PubMed ID: 22986904
    [Abstract] [Full Text] [Related]

  • 40. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways.
    Potter C, Cordell HJ, Barton A, Daly AK, Hyrich KL, Mann DA, Morgan AW, Wilson AG, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS), Isaacs JD.
    Ann Rheum Dis; 2010 Jul 15; 69(7):1315-20. PubMed ID: 20448286
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.